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Memory consolidation requires synaptic reconﬁguration dependent upon extracellular matrix (ECM) molecules interacting with
cell adhesion molecules. Matrix metalloproteinase (MMP) activity is responsible for transient alterations in the ECM that may be
prerequisite to hippocampal-dependent learning. In support of this hypothesis we have measured increases in MMP-3 and MMP-
9 levels within the hippocampus and prefrontal cortex during Morris water maze training. The present investigation extends
these ﬁndings by determining that infusion of an MMP inhibitor (FN-439) into the dorsal hippocampus disrupted acquisition of
this task. In vitro ﬂuorescence enzyme assays to determine the speciﬁcity of FN-439 against the catalytic domains of MMP-3 and
MMP-9indicatedmean
￿SEMIC50sof16.2
￿7.8and210.5
￿37.8µM,respectively,whileinsituzymographyusinghippocampal
sections treated with FN-439 indicated signiﬁcant reductions in MMP gelatinase activity. These results suggest that compromising
theabilityofthedorsalhippocampustoreconﬁgureECMmoleculesbyinhibitingMMPactivityinterfereswithappropriatespatial
memory acquisition, and support a role for hippocampal MMPs in the phenomena of spatial memory acquisition and storage.
Copyright © 2007 John W. Wright et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Extracellular matrix (ECM) molecules mediate changes in
the brain’s synaptic architecture thought to be critical to
the processes of neural plasticity, learning, and memory [1–
3]. The ECM is composed of secreted glycoproteins and
proteoglycans that form a network to which neurons and
glia adhere. The interaction among cells and the ECM is
dependent upon several types of cell adhesion molecules
(CAMs) including integrins, cadherins, and neural cell adhe-
sion molecules (see [4, 5] for reviews). ECM molecules make
possible a wide range of signaling designed to inﬂuence cel-
lularproliferation,growth,movement,synapticstabilization,
and apoptosis (see [6, 7] for reviews).
Matrix metalloproteinases (MMPs) are a family of pro-
teinases important to the maintenance and restructuring
of the ECM [8–10]. MMPs modulate growth cone exten-
sion, neurite development, synaptic transmission and long-
term modiﬁcation, and neuronal degeneration [6, 11–14].
These processes are essential to successful neural plastic-
ity. MMP activity is kept in check by tissue inhibitors of
metalloproteinases (TIMPs) that form tight noncovalent
complexes with them, thus preventing enzymatic activity
[1, 15, 16]. MMP-9 is involved in the remodeling accom-
panying kainic acid-induced epileptogenesis [17, 18], and
deaﬀerentation-induced sprouting in the dentate gyrus [19].
The potential contribution of ECM remodeling to learn-
ing and memory has only recently been addressed [5, 6, 20–
24]. Our laboratory has focused on hippocampal mediated
spatial memory and measured elevations in hippocampal
MMP-3 and MMP-9 during acquisition of the Morris water
maze task [25, 26]. The MMP inhibitor (MMPi) FN-439 in-
terfered with the late-phase of long-term potentiation (LTP),
and when infused intracerebroventricularly (icv) disrupted
the acquisition of the Morris water maze task [27].
The present investigation further evaluated the poten-
tial role of MMPs in spatial learning. The hippocampus has
been shown to mediate the acquisition of spatial memory
[28–32], and the dorsal hippocampus is especially impor-
tant in this regard [33, 34]. Thus, we bilaterally infused FN-
439 into the dorsal hippocampus in an attempt to disrupt2 Neural Plasticity
performance on the Morris water maze task over 8 days of
training.Membersofanadditionalgroupofanimalswereicv
infused with FN-439 for comparison. The following speciﬁc
questions were addressed. (1) Can bilateral infusions of an
MMPi into the dorsal hippocampus block the acquisition of
a spatial learning task? (2) Is the magnitude of hippocampal
MMPi-induced interference with the acquisition of this task
equivalent with that of icv delivered MMPi? (3) How speciﬁc
is FN-439 against MMP-3 and MMP-9?
2. EXPERIMENTAL PROCEDURES
2.1. Animalsandsurgicalprotocol
The protocols utilized in this investigation minimized pain
anddiscomfort,wereapprovedbytheWashingtonStateUni-
versity Institutional Animal Care and Use Committee, and
conformed to the guidelines for the care and use of labora-
tory animals as required by the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 80-23). Male Sprague-Dawley rats (300–
350g, breeding stock derived from Taconic, Germantown,
NY) were adapted to a 12-hour light/dark cycle initiated at
0600 hour in the American Association for the Accreditation
of Laboratory Animal Care approved vivarium at a tempera-
ture of 21
￿ 1
ÆC. The animals were housed in pairs and pro-
vided with water and food (Harlan Teklad F6 Rodent Diet,
Madison, WI) ad libitum except the night prior to surgery
when food was withheld. Each animal was prepared with bi-
lateral guide cannulas targeting either the dorsal hippocampi
(ﬂat skull coordinates relative to bregma: post:
￿4.0mm, lat:
￿2.5mm from midline) or lateral ventricles (post: 1.0mm,
lat:
￿1.5mm from midline) under ketamine-xylazine anes-
thesia (100 and 2mg/kg, resp., intramuscularly). The guide
was constructed from PE-60 tubing (Clay Adams, Parsip-
pany, NJ) with a heat bulge that rested on top of the cra-
nium thus serving as a stop to further penetration. The to-
tal length of the guide was 2.5cm with a distance from the
beveled tip to the heat bulge of 2.0 and 2.5mm for the dorsal
hippocampus and icv, respectively. All infusions were made
usinga30-gaugestainless-steeltubinginjectorwithabeveled
end that protruded 2.0mm beyond the tip of the PE guide
cannula. The injector was attached to a 10µLH a m i l t o ns y -
ringe by PE-20 tubing. The animals were hand gentled for 5
minutes per day during the 7 days of recovery from surgery.
Thoseanimalspreparedwithdorsalhippocampusguidecan-
nulas were randomly assigned to one of two groups (8 rats
each) that received either FN-439 or artiﬁcial cerebrospinal
ﬂuid vehicle (aCSF; in mM: 124 NaCl, 3 KCl, 1.24 KH2PO2,
1.3 MgSO4,2 . 0C a C l 2,2 6N a H C O 3, and 10 D-glucose).
Those animals prepared with icv cannulas were similarly as-
signed.
2.2. MMPinhibitor
Reeves et al. [19] determined that a 7.2mM stock of FN-439
(4-Abz-Gly-Pro-D-Leu-D-Ala-OH, mw = 490.6; MMP in-
hibitor 1 #444250, Calbiochem, San Diego, Calif) in aCSF
infused over 30 minutes to a total volume of 100µL (350µg),
inhibited MMP-9 activity by 83.6% as compared with aCSF
infusedcontrolanimals.Ourlaboratory[27]previouslyused
a 7.2mM stock in aCSF icv infused over 5 minutes to a to-
tal volume of 10µL( 3 5µg) 10 minutes prior to behavioral
testing, and again 3 hours post-testing (cumulative dose =
70µg). Presently, we utilized a 14.4mM stock in aCSF in-
fused over 1 minute to a total volume of 5µL, that is, 2.5µL
for each side (17.5µgi n2 . 5µL aCSF/min) 20 minutes prior
to behavioral testing (5 trials), and again 10 minutes after
testing(cumulativedose=70µg)eachday.Theprotocolused
foricvinfusionwas35µgin5µLaCSFinfusedover1minute,
20 minutes prior to testing and again 10 minutes following
testing (cumulative dose = 70µg). Behavioral testing in the
Morris water maze task was conducted by an experimenter
blind to the treatment of each animal.
2.3. Morriswatermazetask
The Morris water maze task [30] was used to test spatial
memory acquisition. This protocol has been described in de-
tail [35]. Brieﬂy, each trial entailed placing the animal into
the water facing the wall of the pool (1.6m in diameter
painted black, ﬁlled to a depth of 30cm) at one of four lo-
cations (North (N), South (S), East (E), and West (W)) and
tracking its swimming path and duration (Chromatrac; San
Diego Instruments, San Diego, Calif) until the submerged
platform was found (12cm in diameter painted black, 2cm
below the surface). Swim speed was determined from these
values. If the animal located the platform within 120 sec-
onds it was permitted 30 seconds on the platform before
the next trial commenced. If the animal did not ﬁnd the
platform it was placed on the platform and allowed a 30-
second rest period. The animal’s entry point was random-
ized on each trial, and the location of the platform was
randomly assigned to one of the four quadrants and re-
mained ﬁxed for each animal throughout training (5 tri-
als/day for 8 days). At the conclusion of the 5 acquisition
trials on day 8 each animal was administered one probe
trial. During this probe trial (120 seconds) the platform
was removed and the time spent within the target quadrant,
and the number of crossings into the target quadrant, were
recorded.
We also compared the groups concerning positive thig-
motaxis on day 8 of training. Since the duration of each of
the 5 trials on day 8 depended on how quickly the rat located
the platform, the time spent next to, or near (within 20cm),
the wall of the maze was divided by total time of the trial. A
ratio was determined for each of the 5 trials and the mean of
theseﬁveratioswascalculatedforeachanimalandsubmitted
to one-way ANOVA.
2.4. Histologicalexamination
Oncebehavioraltestingwascompletedeachanimalprepared
with hippocampal cannulas was deeply anesthetized using
Equithesin (pentobarbital: 100mg/kg, IP, Jensen-Salsbury
Labs, Kansas City, Mont) and transcardally perfused withJohn W. Wright et al. 3
0.15M NaCl followed by 10% formalin. Brains were re-
moved and stored in a 30% sucrose in 10% formalin so-
lution at 4
ÆC for at least 7 days. Each brain was then hor-
izontally sectioned through the hippocampus (40µm) us-
ing a freezing microtome (Spencer Lens, Buﬀalo, NY). The
sections were mounted on gelatin-coated slides and stained
with Cresyl violet. The slides were cover-slipped and viewed
using an overhead slide projector (Model X-1000, Ken-A-
Vision, Raytown, Mont), thus permitting localization of the
guide cannula and injector tracts using Paxinos and Wat-
son’s atlas [36]. The location of the tip of the injector
ranged from
￿3.6t o
￿4.5mm posterior to bregma, lateral
2.2 to 3.0mm, and ventral to the surface of cortex 2.2–
2.8mm.
Those animals prepared with icv cannulas were anes-
thetized and injected with 5µLo ff a s tg r e e nd y e .T h eb r a i n
was extracted and ventricles were checked for dye. All can-
nulas were appropriately placed.
2.5. MMPenzymeassay
EnzymeassaysforMMPactivitywereconductedinblack96-
well plates according to manufacturer instructions (Biomol
International LP, Plymouth Meeting, Pa). Catalytic domains
for MMP-3 and -9 were used with the ﬂuorogenic peptide
substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.S o l u -
tionswerepreincubatedwithFN-439for30minutesat37
ÆC.
Subsequently, the ﬂuorogenic peptide substrate was added
and ﬂuorescence was measured at 10-minute intervals for
one hour using a Perkin-Elmer plate reader. Slopes were de-
rived from the linear portion of the curves and background
slopesweresubtractedfromallsamples.Theslopeswerenor-
malized as percent of enzyme activity compared with activ-
ity in the absence of inhibitor. IC50 values were extrapolated
using quadratic and sigmoidal curve ﬁt programs for each
sample and were averaged.
2.6. Insituzymography
Na¨ ıve rats were euthanized by decapitation, their brains were
sectioned (10µm) using a cryostat and the sections were
mounted on slides and stored at
￿80
ÆC for no longer than a
week. These sections were warmed to room temperature for
10 minutes and preincubated for 3 hours in either PBS (pH
7.4 control) or 14.4mM FN-439 in PBS at 37
ÆC. The control
slides were then incubated for an additional hour with DQ-
gelatin-FITC (DQ, Molecular Probes, Eugene, Ore) and the
treated slides were incubated with DQ containing 14.4mM
FN-439 for 1 additional hour. Following incubation, the
slides were washed in PBS, ﬁxed with 4% paraformaldehyde
in PBS, and cover slipped using prolong antifade mounting
medium containing DAPI (Molecular Probes, Eugene, Ore).
The slides were examined using a Zeiss Axioplan 2I micro-
scope using epiﬂuorescent illumination and appropriate ﬁl-
ter sets for visualizing DQ (FITC) and DAPI (UV) ﬂuores-
cence. Images were captured at 100–200X magniﬁcation us-
ing a Kodak DC290 digital camera and Photoshop software
(Adobe Systems Inc, San Jose, Calif).
2.7. Statisticalanalyses
The mean latencies and distances to ﬁnd the platform and
swim speeds during each daily block of ﬁve trials in the wa-
ter maze were analyzed using Groups X Days ANOVAs, with
repeated measures on the second factor. One-way ANOVAs
were utilized to test for potential diﬀerences among the
groups on days 1 and 8 of acquisition, to compare levels of
thigmotaxis (swimming near the walls of the maze) on day 8
oftraining,andregardingtimespentwithin,andthenumber
of crossings into, the target quadrant during probe trials. All
signiﬁcant eﬀects from ANOVA analyses were further eval-
uated using Newman-Keuls post hoc tests with the level of
signiﬁcance set at P<. 05.
3. RESULTS
3.1. Morriswatermazeperformance
Figure 1 presents the mean
￿ SEM latencies (panel (a)) and
distances swum (panel (b)) to ﬁnd the submerged platform
for each group over the 8 days of acquisition training. These
groups were not diﬀerent regarding latencies to ﬁnd the plat-
form at the initiation of training on day 1 (F3,28 = 0.27,
P>. 10). However, the overall results from the 4 (groups)
￿8 (days) ANOVA indicated that both groups treated with
MMPi evidenced impaired acquisition as compared with
aCSF infused groups (F3,28 = 2.97, P<. 05). There was also
an expected days eﬀect (F7,196 = 58.41, P<. 0001); however,
the interaction was not signiﬁcant (F21,196 = 1.04, P>. 10).
Post hoc analyses of the days eﬀect indicated that latencies
on days 5–8 were less than those on days 1–3, and days
3 and 4 were less than days 1 and 2 of acquisition. There
were group diﬀerences on day 8 of acquisition (F3,28 = 8.95,
P<. 001). Those animals injected with MMPi into the dor-
sal hippocampus or icv required signiﬁcantly longer search
times than those that received aCSF into the hippocampus
or icv (day 8 mean
￿ SEM latencies: 37.9
￿ 8.4, 44.4
￿ 10.7,
13.4
￿ 1.0, and 14.3
￿1.9s,resp.).
One-way ANOVA indicated that the groups were not
diﬀerent on day 1 of acquisition regarding distances swum
to ﬁnd the platform (F3,28 = 0.84, P>. 10; Figure 1(b)).
The 4 (groups)
￿8( d a y s )A N O V Ar e v e a l e dag r o u p se ﬀect
(F3,28 = 3.54, P<. 05), a signiﬁcant days eﬀect (F7,196 = 9.89,
P<. 0001), but no interaction (F21,196 = 1.15, P>. 10). Post-
hoc analyses of the groups eﬀect indicated that both groups
givenMMPiswamgreaterdistancestoﬁndtheplatformthan
those injected with aCSF. Post hoc analyses of the days ef-
fect suggested that distances on days 4–8 were less than those
of days 1 and 2. Finally, there were group diﬀerences on day
8( F 3,28 = 7.08, P<. 005). Those rats injected with MMPi
into the hippocampus or icv swam signiﬁcantly longer dis-
tances to ﬁnd the platform than those given aCSF into the
hippocampus or icv (12.1
￿ 2.9, 12.9
￿ 2.7, 4.2
￿ 0.5, and
5.8
￿0.7m,resp.).
Those rats injected with aCSF displayed superior search
strategies as compared with members of both MMPi treated
groups (Figure 2). This was illustrated by group diﬀerences
in positive thigmotaxis, that is, swimming at or near the4 Neural Plasticity
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Figure 1: Mean
￿ SEM group changes in latencies (a) and distances (b) to locate the platform in the Morris water maze during 8 acquisition
days. Five trials were administered per day with the location of the platform ﬁxed during training for each animal. Bilateral injections
of an MMP inhibitor (MMPi: FN-439) into dorsal hippocampi (Hipp) or intracerebroventricularly (icv) signiﬁcantly interfered with the
acquisition of the task. In contrast, bilateral injections of the vehicle, artiﬁcial cerebrospinal ﬂuid (aCSF), into dorsal hippocampi or icv did
not interfere with the acquisition of this task of spatial memory. Those groups injected with MMPi revealed signiﬁcantly longer latencies to
ﬁnd the platform than the aCSF injected groups on days 5–8 of acquisition.
￿P<. 05.
walls of the maze (F3,28 = 9.09, P<. 001). Post hoc anal-
yses indicated that those animals infused with MMPi into
the hippocampus (0.37
￿ 0.09) or icv (0.45
￿ 0.11) revealed
greater thigmotaxic tendencies than those animals infused
with aCSF into the hippocampus (0.17
￿0.06) or icv (0.14
￿
0.05).
Results from probe trials conducted at the conclusion of
acquisition training on day 8 are presented in Figure 3,a n d
indicated diﬀerences among the groups regarding time spent
in the target quadrant (F3,28 = 9.08, P<. 001). Post hoc anal-
yses indicated that those animals injected with aCSF into the
hippocampusoricv(40.7
￿2.2and47.1
￿4.0s,resp .)revealed
signiﬁcantly greater time spent in the target quadrant than
those rats treated with MMPi into the hippocampus or icv
(34.3
￿2.7and28.4
￿0.8s,resp.).Thegroupthatreceivedicv
MMPi indicated signiﬁcantly less time in the target quadrant
than the other groups. There were no diﬀerences considering
the number of entries into the target quadrant (F3,28 = 0.98,
P>. 10). Nor were there diﬀerences in overall swim speeds
during the 8 days of training for those groups treated with
MMPi into the hippocampus or icv, and those injected with
aCSF into the hippocampus or icv (0.32
￿ 0.02, 0.31
￿ 0.02,
0.30
￿0.02, and 0.31
￿0.02m/s, resp.).
3.2. MMPenzymeassay
The mean
￿ SEM IC50 values for MMP-3 and -9 were de-
termined to be 16.2
￿ 7.8 and 210.5
￿ 37.8µM, respectively,
indicating high speciﬁcity against MMP-3 (stromelysin-1)
and reasonably good speciﬁcity for MMP-9 (gelatinase B)
(Figure 4). These IC50 values were the reverse of those re-
ported by Odake et al. [37], that is, 30µM against gelati-
nase and 150µM against stromelysin. There are at least two
possible explanations for these diﬀerences. First, Odake and
colleagues used HSF stromelysin and HG gelatinase as sub-
strates, while we used MMP-3 (stromelyisin-1) and MMP-9
(gelatinase B). Second, we used only the catalytic domains of
MMP-3 and MMP-9.
3.3. Insituzymography
Figure 5 presents the results of incubating hippocampal sec-
tions with PBS or 14.4mM FN-439 on MMPs (green ﬂuo-
rescence) in situ. A similar appearance of cell nuclei (blue
ﬂuorescence) was noted comparing control (PBS) and FN-
439 treatedsections,suggestingno cellulartoxicity. Thebasal
activity of MMP-9 was signiﬁcantly reduced following FN-
439 treatment as indicated by a lack of green ﬂuorescence.
These in situ results suggest that FN-439 signiﬁcantly inhib-
ited MMP-2 and MMP-9 in the hippocampus.
4. DISCUSSION
The present investigation was designed to further evaluate
the ability of an MMP inhibitor to inﬂuence acquisition of a
spatial memory task. We were particularly interested in de-
termining the speciﬁcity of FN-439 and whether infusion
of this inhibitor into the dorsal hippocampus disrupted ac-
quisition of a spatial memory task. The in vitro ﬂuores-
cence assay results demonstrated that FN-439 had a maximalJohn W. Wright et al. 5
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Figure 2: Representative examples of search patterns in the Mor-
ris water maze during a 120-second trial on day 8 of acquisition
training by one member of each group. Latency (Lat) and distance
(Dist) to ﬁnd the platform are provided for each rat. Bilateral in-
jection of MMPi into dorsal hippocampi (Hipp) or icv resulted in
impaired search patterns characterized by frequent swimming near
the walls of the maze (positive thigmotaxis). Those animals injected
with aCSF into dorsal hippocampi or icv displayed superior search
patterns culminating in short latencies and distances to ﬁnd the
platform. Members of these groups did not diﬀer with respect to
swim speeds which ranged from 0.30 to 0.32m/s.
eﬀect upon the MMP-3 catalytic domain and good speci-
ﬁcity for the MMP-9 catalytic domain. In situ zymography
further determined that FN-439 signiﬁcantly reduced MMP
gelatinaseactivityinhippocampal sectionsascomparedwith
PBS controls. In a previous investigation Reeves et al. [19]
used a signiﬁcantly larger icv dose of FN-439 (350µg) than
in the present study (70µg), following unilateral lesions of
the entorhinal cortex resulting in “collateral sprouting of
the crossed temporodentate ﬁber pathway.” These rats were
shown to lack the ability to demonstrate LTP in the sprout-
ing pathway. This points to an important role for MMPs in
the process of synaptogenesis and the capacity to form LTP
in the deaﬀerentation/sprouting model.
Presently, FN-439 signiﬁcantly interfered with the acqui-
sition of the Morris water maze task of spatial learning and
was equivalently eﬀective whether infused into the dorsal
hippocampus or icv delivered. Group diﬀerences in rate of
acquisition could not be attributed to diﬀerences in swim
speed. Although we have not tested FN-439 for hippocam-
palpenetrability,wehavepreviouslyshownthaticvdelivered
radio labeled small peptides inﬂuence c-fos expression in the
hippocampus [38]. It is likely that this low molecular weight
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Figure 3: Mean
￿ SEM time spent by members of each group in
the target quadrant during one 120-second probe trial (platform
removed) following acquisition training on day 8 in the Morris wa-
ter maze. Bilateral injection of an MMPi into dorsal hippocampi or
icv signiﬁcantly reduced time spent in the target quadrant as com-
pared with bilateral injection of aCSF. Those animals icv injected
with MMPi revealed the least time spent in the target quadrant
(28.4
￿0.8 seconds) followed by those injected with MMPi into the
dorsal hippocampi (34.3
￿2.7 seconds). Those groups injected with
the aCSF into the dorsal hippocampi or icv displayed signiﬁcantly
greater spent time (40.7
￿2.2a n d4 7 .1
￿ 4.0s,resp.).
￿P<. 05.
inhibitor is also capable of penetrating the hippocampus and
inﬂuencing signaling when icv injected. There were group
diﬀerences comparing probe trial results with the aCSF in-
fused groups revealing greater time spent in the target quad-
rantthantheMMPitreatedgroups.Thedegreeofpersistence
to enter and remain in the target quadrant has been utilized
as a measure of successful acquisition. Although we presently
noted MMPi-induced interference with appropriate acquisi-
tion of this task a larger dose of this inhibitor would be ex-
pected to have an even greater negative impact on perfor-
mance. Related to this, the daily infusion volume of 2.5µL
over one minute into the dorsal hippocampus may have re-
sulted in tissue damage that could explain the decreased per-
sistence of the group given aCSF to stay in the target quad-
rant during probe trials as compared with the group given
icv aCSF.
Nagy et al. [3], Meighan et al. [27], and the present in-
vestigation move this research area towards the establish-
mentofacausalrelationship betweenchangesinbrainMMP
expression and learning. Nagy and colleagues reported that
the treatment of hippocampal slices with an MMP-2/9 in-
hibitor disrupted late-phase LTP but did not aﬀect early-
phase LTP. Similar results were obtained using MMP-9 null
mutant mice. In agreement with a previous paper from our
laboratory [27] the present ﬁndings suggest a link between
inhibition of hippocampal MMP-3 and -9 and signiﬁcantly6 Neural Plasticity
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Figure 4: Results from ﬂuorescence enzyme assays to establish
the speciﬁcity of FN-439 for the catalytic domains of MMP-3 and
MMP-9. The slopes were derived from the linear portion of the
curves and background slopes were subtracted from all samples.
Theslopeswerenormalizedaspercentofenzymeactivitycompared
with activity in the absence of inhibitor. IC50 values were extrapo-
lated using quadratic or sigmoidal curve ﬁt programs for each sam-
ple and averaged. The determined mean
￿ SEM IC50s for MMP-3
and MMP-9 were 16.2
￿7.8 and 210.5
￿37.8µM.
DAPI FITC Merge
(a)
(b)
Figure 5: Representative in situ zymography results demonstrating
gelatinase activity by MMPs in the dentate gyrus in the presence of
(a) PBS (control condition) upper panels or (b) FN-439 (14.4mM)
lowerpanels.Theequivalentblueﬂuorescenceofcellnucleisuggests
no cellular toxicity. MMP-2and MMP-9activity, visualized as green
ﬂuorescence, was signiﬁcantly inhibited by FN-439 as evidenced by
reductions in green ﬂuorescence.
reduced ability to acquire a spatial memory task, and es-
tablish an important role for changes in MMP-3 and -9 ex-
pression within the dorsal hippocampus in the mediation of
spatial memory formation. Thus, these results add further
support to earlier work indicating that ECM molecules are
intimately involved in the modulation of synaptic remodel-
ing and connectivity [10, 21, 24, 39–42].
In summary, hippocampal MMP-3 and MMP-9 appear
to be instrumental in the activation and maintenance of the
neural plasticity presumed to underlie spatial learning and
memory. In the context of current models of memory en-
coding and consolidation [7], compromising the ability of
the dorsal hippocampus to reconﬁgure ECM molecules by
interfering with MMP activity appears to prevent appropri-
ate memory acquisition, and in turn its ability to pass the
stored memory onto other locations (e.g., prefrontal cortex)
for long-term storage.
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